PMID- 23973134
OWN - NLM
STAT- MEDLINE
DCOM- 20140325
LR  - 20231110
IS  - 1522-9653 (Electronic)
IS  - 1063-4584 (Print)
IS  - 1063-4584 (Linking)
VI  - 21
IP  - 9
DP  - 2013 Sep
TI  - Nerve growth factor: an update on the science and therapy.
PG  - 1223-8
LID - S1063-4584(13)00840-6 [pii]
LID - 10.1016/j.joca.2013.06.004 [doi]
AB  - OBJECTIVE: Nerve growth factor (NGF) is a key regulator of nociceptive pain and 
      thus appears to be an interesting target molecule for an innovative class of 
      analgesic medication. We set out to review the principles of neurogenic 
      inflammation and results of anti-NGF regimens in animal studies as well as 
      clinical trials with patients with back pain and osteoarthritis (OA). DESIGN: We 
      searched using Google Scholar Search and Pubmed as well as through conference 
      reports for articles and abstracts related to NGF and clinical trials using 
      anti-NGF regimens. We report on efficacy findings and adverse events (AEs) 
      related to these agents in this review. RESULTS: We identified five full articles 
      and eight abstract reports relating to anti-NGF agents studied for use in back 
      pain and in OA. CONCLUSIONS: Anti-NGF agents either alone or in combination with 
      non-steroidal anti-inflammatory agents (NSAIDs) were more efficacious for the 
      treatment of pain in a number of trials of knee and hip pain compared to NSAIDs 
      alone. However, adverse effects that included rapidly progressive OA and joint 
      replacement were more common in patients treated with anti-NGF and NSAIDs than 
      either treatment alone. Anti-NGF treatment related neurologic symptoms including 
      paresthesias, and potentially other types of adverse effects were usually 
      transient but warrant additional investigation.
CI  - Copyright (c) 2013. Published by Elsevier Ltd.
FAU - Seidel, M F
AU  - Seidel MF
AD  - Medizinische Klinik und Poliklinik III, University Hospital, Section of 
      Rheumatology, Sigmund-Freud-Strasse 25, D-53127 Bonn, Germany. 
      Matthias.Seidel@ukb.uni-bonn.de
FAU - Wise, B L
AU  - Wise BL
FAU - Lane, N E
AU  - Lane NE
LA  - eng
GR  - K24 AR048841/AR/NIAMS NIH HHS/United States
GR  - P50 AR060752/AR/NIAMS NIH HHS/United States
GR  - K12 HD051958/HD/NICHD NIH HHS/United States
GR  - P50 AR063043/AR/NIAMS NIH HHS/United States
GR  - K12HD051958/HD/NICHD NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - England
TA  - Osteoarthritis Cartilage
JT  - Osteoarthritis and cartilage
JID - 9305697
RN  - 0 (Analgesics)
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 9061-61-4 (Nerve Growth Factor)
RN  - EQL0E9GCX1 (tanezumab)
SB  - IM
MH  - Analgesics/administration & dosage/adverse effects
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/adverse effects
MH  - Antibodies, Monoclonal, Humanized/*administration & dosage/adverse effects
MH  - Back Pain/*drug therapy
MH  - Humans
MH  - Nerve Growth Factor/*antagonists & inhibitors
MH  - Neuritis/*drug therapy
MH  - Osteoarthritis/*drug therapy
PMC - PMC4252012
MID - NIHMS643269
OTO - NOTNLM
OT  - Nerve growth factor
OT  - Neurogenic inflammation
OT  - Osteoarthitis
OT  - Receptor antagonists
COIS- Competing interests BLW has received research funding within the last year from 
      Pfizer, Inc. NEL has no competing interests in the last year. MFS has served on a 
      Pfizer board last year.
EDAT- 2013/08/27 06:00
MHDA- 2014/03/26 06:00
PMCR- 2014/12/02
CRDT- 2013/08/27 06:00
PHST- 2013/01/23 00:00 [received]
PHST- 2013/05/30 00:00 [revised]
PHST- 2013/06/05 00:00 [accepted]
PHST- 2013/08/27 06:00 [entrez]
PHST- 2013/08/27 06:00 [pubmed]
PHST- 2014/03/26 06:00 [medline]
PHST- 2014/12/02 00:00 [pmc-release]
AID - S1063-4584(13)00840-6 [pii]
AID - 10.1016/j.joca.2013.06.004 [doi]
PST - ppublish
SO  - Osteoarthritis Cartilage. 2013 Sep;21(9):1223-8. doi: 10.1016/j.joca.2013.06.004.